Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 506380Generated: November 2, 2026

Ethyl Acetate → (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-pyrimidin-2-yl]}amino-2,6-diethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester

https://huagongshe.com/reaction/506380

Reaction equation

Participants

RoleNameHCIDCharge
ReactantEthyl AcetateHCID 8857—
ReactantSodium BicarbonateHCID 516892—
Reactant(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl esterHCID 86610603—
ReactantTriethylaluminum hexaneHCID 86610617—
CatalystCuprous chlorideHCID 62652—
CatalystHCID 178418397HCID 178418397—
CatalystHCID 178418647HCID 178418647—
Solvent1,4-DioxaneHCID 31275—
Product(2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-pyrimidin-2-yl]}amino-2,6-diethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl esterHCID 86610616—

Reaction Conditions

Temperature60 °C

Reaction Steps

(2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-trifluoromethanesulfonyloxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (250 mg) is dissolved in 1,4-dioxane (3 ml), and thereto are added a catalytic amount of tetrakis(triphenylphosphine)palladium, a catalytic amount of silver carbonate and a catalytic amount of copper (I) chloride under nitrogen flow. After adding dropwise a triethylaluminum-hexane solution (1M, 480 μl), the mixture is stirred at 60° C. for 30 minutes. After cooling to room temperature, a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate are added to the reaction solution. The organic layer is washed with a saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue is purified by column chromatography (NH-silica gel; hexane: ethyl acetate=9:1→4:1) to give (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)-pyrimidin-2-yl]}amino-2,6-diethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (83 mg); MS (m/z): 667 [M+H]+ and (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester (77mg). MS (m/z): 639 [M+H]+.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS07781443B2
Source datasetuspto-grants-2010_08
ORD IDord-bdc5c63aa14847d5b24a64243b0b5713
Source noteuspto-grants-2010_08